Germline BRCA, Chemotherapy Response Scores, and Survival in the Neoadjuvant Treatment of Ovarian Cancer

BMC Cancer - United Kingdom
doi 10.1186/s12885-020-6688-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

BRCA Mutations in the Manifestation and Treatment of Ovarian Cancer

Oncotarget
Oncology
2017English

Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer

2012English

Multiagent Neoadjuvant Chemotherapy and Tumor Response Are Associated With Improved Survival in Pancreatic Cancer

HPB
HepatologyGastroenterology
2019English

Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer

JAMA Oncology
Cancer ResearchOncology
2017English

Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

Journal of Medical – Clinical Research & Reviews
2019English

Neoadjuvant Chemotherapy in the Combined Treatment of Gastric Cancer

Onkologiya. Zhurnal imeni P.A.Gertsena
2014English

Phase 1 Trial of Olaparib and Oral Cyclophosphamide in BRCA Breast Cancer, Recurrent BRCA Ovarian Cancer, Non-Brca Triple-Negative Breast Cancer, and Non-Brca Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

Sustained CA19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival

Oncologist
Cancer ResearchMedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy